Co-occurrent Alterations of Alzheimer's Genes and Prostate Cancer Genes in Prostate Cancer
Open Access
- 28 April 2020
- journal article
- research article
- Published by International Institute of Anticancer Research in Cancer Genomics & Proteomics
- Vol. 17 (3) , 271-275
Abstract
Background: Androgen deprivation therapy (ADT) is extensively employed in treatment of prostate cancer. Some studies have found increased risk of Alzheimer's disease and cognitive impairment in patients treated with ADT. Aim: Since the uncertainty about ADT and dementia might relate to the genetics of prostate cancer and Alzheimer's disease, we used the Cancer Genome Atlas (TCGA) to examine the relationship between genes implicated in Alzheimer's disease and genes implicated in prostate cancer in men with prostate cancer. Materials and Methods: The genomics of 492 prostate cancer cases in the Genomic Data Commons TCGA Prostate Cancer data set were examined. Results: Alterations (mutation, amplification or deletion) in prostate cancer gene speckle-type POZ protein (SPOP) significantly co-occurred with alterations in Alzheimer's disease gene bridging integrator-1 (BIN1). Alterations in prostate cancer gene spectrin alpha 1 (SPTA1) significantly co-occurred with alterations in Alzheimer's disease gene CD2-associated protein (CD2AP) (p<0.001). The presence of somatic mutations (deleterious and missense/in frame) in SPOP disturbs BIN1 gene expression. SPOP and BIN1 RNA expression in 492 prostate cancer specimens was significantly positively correlated (p<0.001). Increased expression of SPOP in 492 cases of prostate cancer was associated with reduced survival (p=0.00275). BIN1 forms part of a network that interacts with the MYC oncogene, which is activated at the earliest phases of prostate cancer and is linked to disease aggressiveness. Men receiving ADT had tumor with a significantly higher Gleason score (p=0.023). Gleason score and BIN1 RNA expression in 499 prostate cancer specimens were significantly correlated (p<0.001). Conclusion: The severity of prostate cancer is determined by the genetics of the tumor itself, possibly at least in part by the interactions of SPOP/BIN1, MYC/BIN1 and SPTA1/CD2AP. Oncologists treats higher grade prostate cancer with more ADT, which serves as a surrogate marker for disease severity. A weakness of our study is that we did not examine Alzheimer's disease or dementia at all in patients with cancer, only co-occurrence of genetic alterations. Nevertheless, our analysis of TCGA data does not support the idea that ADT causes Alzheimer's disease or dementia.Keywords
This publication has 19 references indexed in Scilit:
- Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate CancerJAMA Network Open, 2019
- BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through Thr348 phosphorylationActa Neuropathologica, 2019
- Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate CancerJournal of Urology, 2018
- Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targetsNature Genetics, 2018
- The Cancer Genome Atlas: Creating Lasting Value beyond Its DataCell, 2018
- Effects of long‐term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancerCancer, 2016
- Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's diseaseNature Genetics, 2011
- Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancerCritical Reviews in Oncology/Hematology, 2010
- A Structure-based Model of the c-Myc/Bin1 Protein Interaction Shows Alternative Splicing of Bin1 and c-Myc Phosphorylation are Key Binding DeterminantsJournal of Molecular Biology, 2005
- Loss of heterozygosity and tumor suppressor activity ofBin1 in prostate carcinomaInternational Journal of Cancer, 2000